Advanced search
Publication Cover
European Journal of General Practice Volume 17, 2011 - Issue 4
Submit an article Journal homepage
389
Views
2
CrossRef citations to date
0
Altmetric
RESEARCH

Is Rosiglitazone use associated with an increase in intensive eye treatment in diabetic patients? A community based study

Michal ShaniDepartment of Family Medicine Central District, Clalit Health Service, Israel;Department of Family Medicine Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence[email protected]
,
Leonid FeldmanDepartment of Family Medicine Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;Nephrology Division, Assaf Harofeh Medical Center, Zerifin, Israel
,
Igor KaisermanDepartment of Ophthalmology, Barzilai Medical Center, Ashkelon, Israel;Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
,
Julian DresnerDepartment of Family Medicine Central District, Clalit Health Service, Israel;Department of Family Medicine Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Tuvia BaevskyDepartment of Family Medicine Central District, Clalit Health Service, Israel
&
Shlomo VinkerDepartment of Family Medicine Central District, Clalit Health Service, Israel;Department of Family Medicine Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Pages 205-209 | Received 03 Nov 2010, Accepted 13 May 2011, Published online: 11 Jul 2011

References

  • CDC National Diabetes Fact Sheet, 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf (accessed 12 May 2011).
  • Avisar R, Friling R, Snir M, Avisar I, Weinberger D. Estimation of prevalence and incidence rates and causes of blindness in Israel, 1998–2003. Isr Med Assoc J. 2006;8:880–1.
  • DCCT Research Group: The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
  • UKPDS Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
  • The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.
  • Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE, . Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001;119:709–17.
  • Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, . Diabetic macular edema associated with glitazone use. Retina 2006;26:562–70.
  • Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126:793–9.
  • Bosco AA, Lerario AC, Santos RF, Wajchenberg BL. Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetologia 2003;46:1669–75.
  • Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Clin Drug Investig. 2008;28:327–32.
  • Feldman L, Shan MI, Efrati S, Beberashvili I, Baevsky T, Weissgarten J, . Association between rosiglitasone use and the decline in renal function in the patients with diabetes mellitus type 2. J Nephrol. 2010;23:350–6.
  • Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189–95.
  • http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/09/WC500097003.pdf (accessed 12 May 2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.